Bound Therapeutics LLC

Bound Therapeutics LLC We create next-generation microRNA platform technology to bring innovation into cancer therapeutics. U.S. 6,180,767, 2001).

Bound Therapeutics LLC executed an exclusive license from Thomas Jefferson University to use our novel platform technology (Compositions and Methods of Using MicroRNA Inhibitors, PCT/US2015/015681) to develop microRNA therapeutics and diagnostics. Preliminary data showed that our proprietary lead compound designed using our platform reversed off-target effects from conventionally designed microRNA

-blocking agents in a triple negative breast cancer cell model. Bound Therapeutics agents achieve cancer cell-specific delivery of the lead compound through receptor-mediated endocytosis by conjugation with a small peptide (Wickstrom and Basu, Peptide Nucleic Acid Conjugates. Our platform yields single molecule agents that circulate and enter cells with no need for liposome or nanoparticle formulations. We will optimize agents for the needs of each target and customer. Triple negative breast cancer (TNBC) is an aggressive form of breast cancer at a later stage. TNBC accounts for 10-15% of all breast cancers, striking and killing about 28,000 American women each year. There is a tremendous gap in treating TNBC due to the lack of effective targeted agents. The only available supplemental option for chemotherapy, Avastin, was invalidated by FDA for the breast cancer indication in 2011 as a result of poor clinical outcome and safety issues. Drugs in the late stage pipeline are all poly(ADP-ribose) polymerase (PARP) inhibitors. These are only modestly effective in treating a small subset of TNBC patients. Currently only routine chemotherapy is the standard of care, with significant side effects that aggravate the suffering of patients. Therefore, a new molecular therapeutic agent that works in conjunction with chemotherapy with greater
efficacy, specificity, and safety will bridge the gap in
TNBC therapy. Bound Therapeutics designs novel molecular targeting agents that comprise an attractive option for patients. We minimize side effects through a platform technology that enables cancer cell-specific delivery of all compounds. Faster response, decreased dosage, and decreased side effects will reduce the longterm cost of disease management.

06/14/2019

RNA Blockade to Treat Triple Negative Breast Cancer
(PHILADELPHIA, 14 June 2019): The US National Cancer Institute has awarded Bound Therapeutics LLC a Small Business Technology Transfer grant starting 15 June for $300,000 to develop “microRNA-21 Blockade of Triple Negative Breast Cancer”.
"Triple negative breast cancer strikes younger women, tragically killing half the patients within 4 years," said Dr. Yuan-Yuan Jin, Chief Operating Officer of Bound Therapeutics LLC. “Surgery, chemotherapy, and radiation are the current standard of care for triple negative breast cancer.”
“To provide effective molecular therapy that will keep patients alive with a good quality of life, we have designed a cancer cell-targeted drug that will block a tiny strand of ribonucleic acid, called microRNA-21,” explained Dr. Eric Wickstrom, Professor of Biochemistry and Molecular Biology at Thomas Jefferson University, a partner in the award.
Dr. Miguel Castro, President and CEO of Bio-Synthesis Inc., another research partner, said that “The RNA analogs and peptide analogs that we are making to treat triple negative breast cancer cells are extraordinarily specific and safe in mammalian models.”
Our clinical collaborator, Dr. Edith Mitchell, Clinical Professor of Medicine and Medical Oncology at Thomas Jefferson University, commented that “Patients with triple negative disease have limited treatment options compared to patients with more common forms of breast cancer. There is an urgent need for targeted treatments in this area.” Dr. Mitchell serves as the Director of the Jefferson Center to Eliminate Cancer Disparities in diagnosis, treatment, and survival of patients with different ancestries, and is a past President of the National Medical Association.
The funds will enable Bound Therapeutics and its partners Bio-Synthesis Inc. and Thomas Jefferson University to test their drug design in a triple negative breast cancer mouse model with a normal immune system. Early results suggest that microRNA-21 blockade decloaks triple negative breast cancer cells to enable attack by immune cells.
For more information, contact Dr. Yuan-Yuan Jin, 609-969-8259, [email protected]

04/19/2019

If a once-modest regional hospital and its new biotech allies have their way, the capital of Ohio could one day rival America's other biomedical hubs.

04/18/2019

Artificial intelligence will start making a measurable impact in these twelve areas of care by the end of the decade, predicts a panel of experts from Partners HealthCare.

Expecting large growth in the global oligonucleotide industry
04/18/2019

Expecting large growth in the global oligonucleotide industry

NEW YORK, April 17, 2019 /PRNewswire/ -- The global oligonucleotide synthesis market is expected to reach US$ 3,971.72 Mn in 2027 from US$ 1,584.16 Mn in 2018. ...

Diagnostic spin on CRISPR
04/18/2019

Diagnostic spin on CRISPR

Rights are protected for broad use in developing world and for public health needs.

04/18/2019

A team of Tel Aviv University researchers revealed the heart, which was made using a patient’s own cells and biological materials.

Better have dinner early!
04/18/2019

Better have dinner early!

Having an earlier dinner is key to staying healthy -- and how exactly you should be eating during the day

It would be great to save animals!
04/18/2019

It would be great to save animals!

Animal testing is crucial for testing the efficacy and safety of new treatments. It's also a step that everyone would like to avoid as much as possible for a range of economic, regulatory, and ethical reasons. But what are the alternatives, and can they really reduce the use of animals in drug devel...

04/17/2019

Software that can replace doctors for certain tasks has a big responsibility. The Food and Drug Administration is now figuring out how to determine when computer algorithms are safe and effective.

04/17/2019

A team of biologists has uncovered new rules that cells use in making decisions about which genes they activate and under what conditions, findings that add to our understanding of how gene variants affect human traits.

Cancer patients, be aware!!
04/17/2019

Cancer patients, be aware!!

How many people with cancer use complementary and alternative therapies? And do these interfere with conventional treatments? A new study investigates.

Address

Marlton, NJ
08053

Telephone

+1 215-917-4687

Website

Alerts

Be the first to know and let us send you an email when Bound Therapeutics LLC posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Bound Therapeutics LLC:

Shortcuts

Share

Category